Product InformationRegistration Status: Active
CEFTAZIDIME KABI POWDER FOR SOLUTION FOR INJECTION 2G/VIAL is approved to be sold in Singapore with effective from 2016-08-25. It is marketed by FRESENIUS KABI (SINGAPORE) PTE LTD, with the registration number of SIN15075P.
This product contains Ceftazidime 2g/vial in the form of INTRAVENOUS/INTRAMUSCULAR INJECTION, POWDER, FOR SOLUTION. It is approved for INTRAVENOUS use.
This product is manufactured by Labesfal ? Laboratorios Almiro in KOREA, S.A. in REPUBLIC OF, andHanmi Fine Chemical Co. Ltd (Sterile Anhydrous Sodium Carbonate) in PORTUGAL.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Semisynthetic, broad-spectrum antibacterial derived from cephaloridine and used especially for Pseudomonas and other gram-negative infections in debilitated patients.
For the treatment of patients with infections caused by susceptible strains of organisms in the following diseases: lower respiratory tract infections,skin and skin structure infections, urinary tract infections, bacterial septicemia, bone and joint infections, gynecologic infections, intra abdominal infections (including peritonitis), and central nervous system infections (including meningitis).
Mechanism of Action
The bactericidal activity of ceftazidime results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs).
- The absorption of ceftazidime is directly proportional to the size of the dose.
* 115 mL/min
Ceftazidime overdosage has occurred in patients with renal failure. Reactions have included seizure activity, encephalopathy, asterixis, neuromuscular excitability, and coma.
CAZ | Ceftazidim | Ceftazidima | Ceftazidime | Ceftazidime anhydrous | Ceftazidimum | Ceftazidime |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.